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SynaptosomeStress hormone, glutamatergic system, serotonergic system and the noradrenergic system are involved in de-
pressive disorders. However, the relationship among these is still unclear. The present study examined the
effect of dexamethasone (DEX) on the presynaptic glutamate release of synaptosomes from the rat's
prelimbic cortex by using biochemical methods combined with pharmacological approaches. The results
showed that dexamethasone increased the glutamate release of synaptosomes in a dose-dependent manner.
The concentration–response relationship of this effect of DEX was inverse U-shaped with a maximum at
3 μm. Further study showed that glucocorticoid receptor (GR) antagonist and GR siRNA had no effect on
the DEX-induced glutamate release but 5-HT3 receptor antagonist could block the DEX-induced glutamate
release which suggested that DEX produced the increased effect on the glutamate release not by GR, but
through the activation of the 5-HT3 receptors which led to the inﬂux of extrasynaptosomal Ca2+. Moreover,
β3 adrenergic receptor agonist could block the DEX-induced glutamate release. This result suggested that the
effect of DEX on the glutamate release could be regulated by noradrenergic system. The mechanism study
showed that β3 adrenergic receptors regulated the DEX-induced glutamate release via Gs protein–adenylate
cyclase (AC)–protein kinase A (PKA) signal transduction pathway.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Stress is one of the leading predisposing factors in the development
of depression. There is a consistently documented association between
exposure to stressful life events and subsequent onset of episodes of
major depression [1–4]. The stress response involves the activation of
multiple bodily systems, the most prominent of which is the hypotha-
lamic–pituitary–adrenocortical (HPA) axis. This enhanced activity of
the HPA axis creates a neuroendocrine cascade which has been associ-
ated with a greater frequency of episodic release of glucocorticoid.
Excess secretion of glucocorticoid is thought to play a signiﬁcant patho-
physiologic role in the etiology of depression [5,6]. Therefore, the study
of how glucocorticoid causes depression is of important signiﬁcance to
ﬁnd new treatment strategies except classical SSRI/SNRI antidepressants.
Previous studies have proposed that elevated glucocorticoid levels
during stress led to loss of the glucocorticoid receptor (GR)-containingf Medical Neurobiology, Fudan
oad, Shanghai 200032, China.
rights reserved.cells in the hippocampus that mediated the glucocorticoid-induced
suppression of CRH neurons in the paraventricular nucleus [7]. Dexa-
methasone resistance in monkeys was also shown to be associated
with a selective decrease of hippocampal GR [8]. Loss of hippocampal
GR in aged rats may also be pertinent to the increased glucocorticoid
levels of these animals [9] and can be compared to the higher cortisol
levels of older depressed patients compared with younger ones [10].
More recently, the glucocorticoid receptor antagonist, mifepristone
(RU486), has been reported to be effective in the treatment of psychotic
depression [11]. These evidences support the concept that impaired GR
signaling is a key mechanism in the pathogenesis of stress-related de-
pression. Apart from the corticosteroid receptor mechanism of depres-
sion, it has been known that the mechanisms of depression may also
involvemany neurotransmitters. Serotonin, norepinephrine, dopamine
[12] and glutamate [13–16] are proved to underline the mechanism of
depression. A number of studies further suggested that acute stress
was associated with increased excitatory amino acid transmission in
areas of the forebrain. Restraint stress, tail pinch, forced swimming,
footshock, and anxiogenic drugs have been shown to increase the efﬂux
of glutamate as measured by microdialysis in vivo [17,18]. However,
although it is assumed that behavioral stressors can deeply affect gluta-
mate transmission in areas of the forebrain, it is not yet clear whether
glucocorticoid has the direct effect on the presynaptic glutamate
release. We propose that the action of glucocorticoid on glutamatergic
Fig. 1. Concentration-dependence of the effect of dexamethasone on the glutamate re-
lease of synaptosomes from the rat's prelimbic cortex (n=6). Note that in the concen-
tration range of 0.1–30 μM, dexamethasone concentration dependently increased the
glutamate release. The maximum response was induced by 3 μM dexamethasone, indi-
cating that 3 μM was a near saturation concentration.
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the prelimbic cortex, may constitute another important mechanism
for depression, because the prelimbic cortex is an important brain re-
gion involved in cognition and neuropsychiatric processes, and the
glutamate-mediated synaptic inputs to the prelimbic cortex are very
important for the function of the prelimbic cortex [19]. Moreover, ab-
normally enhanced the glutamate release in the prelimbic cortex has
been reported to play an important role in the pathophysiology of neu-
ropsychiatric diseases [20].
Therefore, in the present study we examined the direct effect of
dexamethasone (DEX) on the presynaptic glutamate release by using
in vitro release study in the nerve terminals (synaptosomes) isolated
from the rat's prelimbic cortex. We also studied the precise cellular
mechanisms underlying the inﬂuence of DEX on the glutamate release
by using pharmacological approaches combined with the measure of
the intrasynaptosomal Ca2+ concentration and other techniques. We
have also suggested a possible regulation mechanism for DEX's action.2. Materials and methods
2.1. Chemicals
MDL72222, ethyleneglycol-bis (β-aminoethyl ether) N,N,N′,N′-
tetraacetic acid (EGTA), H89,RU486, amibegron, forskolin, NF449,
SQ22536, β-nicotinamide adenine dinucleotide phosphate (NADP+),
L-glutamate dehydrogenase, and L-glutamate, TES (sodium salt) were
purchased from Sigma-Aldrich (St. Louis, MO). Fluo-3 AM and pluronic
F-127 were purchased from Molecular Probes. Percoll was purchased
from Amersham Biosciences Corporation. Other reagents in AR grades
were products of Shanghai Chemical Plant. MDL72222, EGTA, NADP+,
H89, and L-glutamate were dissolved in ddH2O and others were
dissolved in DMSO. When DMSO was used as the vehicle, drugs were
initially dissolved in 100% DMSO and then diluted into Hanks' balanced
salt solution (HBSS) at a ﬁnal DMSO concentration of 0.1%, which was
conﬁrmed to have no effects on the parameters to be assessed.Fig. 2. Inﬂuence of the glucocorticoid receptor (GR) antagonist and GR siRNA on the DEX-in
course of the action of RU486 (1 μM) on the DEX (3 μM)-induced glutamate release (n=6).
the DEX alone group and RU486+DEX group, n=6, p>0.05. C: immunohistochemistry anal
co-labeled with GR antibody (red) at ﬁve days following vector administration. (a) Untreat
400×). D: bar graph represents percentage of GR-positive neurons (n=5, *pb0.05). E:
DEX-induced glutamate release between the untreated group and GR siRNA group, n=5, p2.2. Synaptosome preparation
Synaptosomes were prepared as described previously [21]. The
prelimbic cortex was dissected and homogenized in 0.32 M sucrose
solution at 4 °C using the Art-Miccra D-8 tissue grinder with a motor-
driven pestle rotating at 900 rpm. The homogenate was centrifuged at
3000 ×g for 3 min at 4 °C. The supernatant (S1) was centrifuged at
14,500 ×g for 12 min at 4 °C. The pellet (P2) was suspended again and
loaded onto Percoll gradients, consisting of three layers of 23%, 10%,
and 3% Percoll in 0.32 M sucrose additionally containing 1 mM EDTA
and 250 μM DTT. The gradients were centrifuged at 32,500 g for
6.5 min at 4 °C. Synaptosomes were harvested from the interface
between the 23% and 10% Percoll layers, and washed in Hanks' balanced
salt solution (HBSS) containing 140 mM NaCl, 5 mM KCl, 5 mM
NaHCO3, 1 mM MgCl2, 1.2 mM Na2HPO4, 10 mM glucose and 20 mM
HEPES, pH 7.4. The washed synaptosomes were centrifuged at
27,000 ×g for 15 min at 4 °C. The protein concentration of the synapto-
somes was determined by the method of Lowry and Rosebrough [22]
with the bovine serum albumin as the standard protein.2.3. Measurement of the glutamate release from synaptosomes
Glutamate release was assayed by on-line ﬂuorimetry as described
previously [23]. Synaptosomal pellets were suspended again by adding
1.5 ml of incubation medium: 122 mM NaCI, 3.1 mM KCI, 0.4 mM
KH2PO4, 5 mM NaHCO3, 20 mM Na-TES(N-[Tris(hydroxymethyl)
methyl]-2-aminoethanesulfonic acid), 1.2 mM Mg2SO4, 16 pM bovine
serum albumin (fatty acid free, type V), and 10 mM D-glucose, pH 7.4.
Additionally, NADP+ (2 mM), glutamate dehydrogenase (50 units/ml)
and CaCl2 (1 mM) were added after 3 min. After incubation of 5 min,
4-aminopyridine (1 mM) or KCl (15 mM) or ionomycin (5 mM) was
added to stimulate glutamate release. The oxidative decarboxylation of
the released glutamate, leading to the reduction of NADP+, was moni-
tored by measuring NADPH ﬂuorescence at excitation and emission
wavelengths of 340 nm and 460 nm, respectively. Data points were
obtained at 60 s intervals. A standard of exogenous glutamate (5 nmol)
was added at the end of each experiment, and the ﬂuorescence change
produced by the addition of exogenous glutamate (5 nmol) was used to
calculate the released glutamate as nmol/mg.2.4. Measurement of the intrasynaptosomal Ca2+ concentration
Puriﬁed synaptosomes were loaded with the acetoxymethyl ester
derivative of the calcium-sensitive ﬂuorescent dye Fluo-3 AM (5.0 μM)
for 30 min at 37 °C [24]. After being washed by centrifugation, the syn-
aptosomes were suspended again in HBSS containing 1.0 mM Ca2+
and 0.5 mM Mg2+. Aliquots (200 μl) of synaptosomal samples were
put into the 96 well plates with a ﬁnal protein concentration of
200–250 μg/ml. The ﬂuorescence intensity was measured at 527 nm in
response to 485 nm excitation with Thermo Scientiﬁc Fluoroskan Ascent
equipped with ﬂuorescent analysis system. The Ca2+ concentration is
expressed as the ﬂuorescence ratiometric ΔF/F0%, which reﬂects a rela-
tive, not an absolute measurement of the free Ca2+ concentration [25].
ΔF/F0%=(F−F0)/F0×100, where F is the ﬂuorescence intensity at each
time point and F0 is the ﬂuorescence intensity of the “rest” level given
by the average of ﬂuorescence intensities before adding a different
reagent.duced glutamate release of synaptosomes from the rat's prelimbic cortex. A: the time
B: the average results in a group of cells; there were no signiﬁcant differences between
ysis of the prelimbic cortices of groups of rats treated in different ways, DAPI (blue) was
ed group (n=5, 400×). (b) Positive control (n=5, 400×). (c) GR siRNA group (n=5,
the average results in a group of cells; there were no signiﬁcant differences of the
>0.05..
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Fig. 3. Inﬂuence of the 5-HT3 receptor antagonist on the DEX-induced glutamate re-
lease of synaptosomes from the rat's prelimbic cortex. A: the time course of the action
of MDL72222 (30 μM) on the DEX (3 μM)-induced glutamate release (n=6). B: the
average results in a group of cells; MDL72222 inhibited the DEX-induced glutamate re-
lease signiﬁcantly. The DEX alone group compared to MDL72222+DEX group, n=6,
#pb0.05.
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Immunoblot analysis of GR, 5-HT3 receptor, and β3 adrenergic recep-
torswas performed on the synaptosomes from the rat's prelimbic cortex.
The synaptosomal pellets were homogenized in a buffer containing
100 mM Tris–HCl, pH 6.7, 1% SDS, 143 mM 2-mercaptoethanol, and 1%
protease inhibitor. The lysate was centrifuged at 12,000 rpm for
10 min at 4 °C. Protein concentrations were determined using a BCA
kit (Pierce Chemicals). The samples were treated with the SDS sample
buffer at 95 °C for 5 min, loaded on a 10% SDS polyacrylamide gel and
blotted to a PVDF membrane. Each blot was incubated with a mouse
anti-glucocorticoid receptor antibody (1:1000; Abcam), a rabbit anti-5-
HT3 receptor antibody (1:1000; Abcam), a rabbit anti-β3 adrenergic re-
ceptor antibody (1:1000; Abcam), or amonoclonal anti-β-actin antibody
(1:4000; Cell Signaling Technology). The horseradish peroxidase devel-
opment systempreviously described [26]was used for immunodetection.
The immunoreactivity was normalized to that of β-actin. Each experi-
ment was repeated at least ﬁve times.
2.6. Intraprelimbic cortical injection and GR siRNA
SD rats were anesthetized with an intraperitoneal injection of
chloral hydrate (400 mg/kg) and secured on a stereotaxic platform.
The coordinates of the mPFC were as follows: for adult SD rats,
anteroposteriorly (AP) from the bregma+3.0 mm, laterally (L) from
the midline+0.7 and +1.5 mm for the left and right, respectively
(10° inclination) and ventrally (V) from the skull −3.8 mm [27]. Thesequences used for the glucocorticoid receptor shRNA were 5′-AAGC
TTCAGGATGTCATTACG-3′. Its design and lentivirus vectors were built
by GeneChem Company. LV-Nr3c1-RNAi or LV-control-RNAi was bilat-
erally injected into the rat's prelimbic cortex, and the other group was
untreated. Each injection was at a rate of 0.2 μl/ min using a 30-gauge
stainless steel needle on a 1 μl Hamilton syringe, held by the microma-
nipulator on the stereotaxic apparatus [28]. The needle remained in
place for another 3 min after each injection to allow for sufﬁcient
diffusion.
2.7. Immunohistochemistry (IHC)
Animals were anesthetized with an intraperitoneal injection of
chloral hydrate (400 mg/kg) and transcardially perfused with saline
followed by 4% paraformalde-hyde in PBS. Tissues were dissected
and post-ﬁxed in the same ﬁxative for 2 h at 4 °C. The tissues were
then transferred to 30% sucrose at 4 °C for 72 h. Prelimbic cortex
(40 μm) sections were cut on a Leica cryostat (CM1800) andmounted
on superfrost plus slides before proceeding to IHC. Non-speciﬁc bind-
ing was blocked by incubation in 3% normal goat serum in PBS with
0.3% Triton X-100 followed by incubation with the primary antibodies
overnight. The antibodies used were: anti-glucocorticoid receptor an-
tibody (1:500, ab2768, Abcam, Cambridge, MA). Slides were washed
in PBS and incubated in appropriate ﬂuorescent secondary antibodies
(goat anti-mouse Cy3, Jackson, USA). After staining of nucleic acids
with DAPI (Sigma, St Louis, MO, USA), slices were analyzed at
400-fold magniﬁcation.
2.8. Off-line data analysis
Off-line data analysis was performed using a Mini Analysis Program
(Synaptosoft), SigmaPlot (Jandel Scientiﬁc) and Origin (Microcal Soft-
ware). Numerical data were expressed as mean±SEM (standard error
of means). Statistical signiﬁcance was determined using Student's
paired t-test for comparisons between two groups or ANOVA followed
by Student–Newman–Keuls test for comparisons among three or
more groups. In all cases ‘n’ refers to the number of samples (different
samples come from different animals) studied.
3. Results
3.1. Dexamethasone increased the glutamate release of synaptosomes
from the rat's prelimbic cortex in a dose-dependent manner
The effect of dexamethasone (DEX) was studied on the glutamate
release from synaptosomes of the prelimbic cortex by on-line ﬂuo-
rimetry. DEX caused a dose-dependent increase of glutamate of
37–150% at the doses tested (control: 9.33±1.00 nmol/mg, n=6;
0.1 μM: 17.13±2.26 nmol/mg, n=6, pb0.05; 0.3 μM: 15.91±
1.15 nmol/mg, n=6, pb0.05; 1 μM: 19.96±3.26 nmol/mg, n=6,
pb0.05; 3 μM: 23.38±1.56 nmol/mg, n=6, pb0.05; 10 μM:
19.70±2.40 nmol/mg, n=6, pb0.05; 30 μM: 12.81±1.62 nmol/mg,
n=6, p>0.05) (Fig. 1). This result was in line with previous ﬁndings
of microdialysis studies in the hippocampus [29], and suggested that
the increased effect of DEX on the glutamate release of synaptosomes
from the rat's prelimbic cortex was dose dependent, with a threshold
concentration between 0.1 μM and 10 μM and a peak glutamate
concentration of 3 μM. These data indicated that DEX exerts a fast
increased effect on the glutamate release.
3.2. Glucocorticoid receptor antagonist, mifepristone (RU486) had no effect
on the DEX-induced glutamate release of synaptosomes from the rat's
prelimbic cortex
To analyze the role of glucocorticoid receptors in the increased effect
of DEX on the glutamate release of synaptosomes, we observed the
Fig. 4. Inﬂuence of EGTA (1 mM) on the DEX-induced glutamate release of synaptosomes from the rat's prelimbic cortex and inﬂuence of MDL72222 on the DEX-induced Ca2+
concentration elevation. A: the time course of the action of EGTA (1 mM) on the DEX (3 μM)-induced glutamate release (n=4). B: the average results in a group of cells, EGTA
inhibited the DEX-induced glutamate release signiﬁcantly. The DEX alone group compared to EGTA+DEX group, n=4, #pb0.05. C: time course of the effect of the DEX (3 μM)
on the intrasynaptosomal Ca2+ concentration in the synaptosomes from the rat's prelimbic cortex and the inﬂuence of MDL72222 (30 μM) on the DEX-induced elevation of
Ca2+ concentration (n=6). D: the average Ca2+ concentration of the effect of the DEX and MDL72222+DEX; the DEX group compared to MDL72222+DEX group, pb0.05;
n=6.
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effect of DEX. The results showed that RU486 (1 μM) alonehad no effect
on the glutamate release. In the presence of the RU486, DEX still
increased the glutamate release (Fig. 2A, n=6). The average concentra-
tion of glutamate after the application of DEX in the presence of RU486
was 32.84±4.17 nmol/mg, which was not statistically signiﬁcant from
DEX alone (30.95±3.78 nmol/mg) (Fig. 2B, n=6, p>0.05).
The GR siRNA results also showed that DEX increased the glutamate
release of synaptosome from GR siRNA rats and the increased effect of
DEX had no statistical signiﬁcance compared with the untreated
group. The average concentration of glutamate after the application of
DEX in the GR siRNA group was 27.93±3.95 nmol/mg, which was not
statistically signiﬁcant from the effect of DEX on the untreated group
(31.30±1.50 nmol/mg) (Fig. 2E, n=5, p>0.05).
These results indicate that the activation of glucocorticoid receptors
may not be the mechanism of the DEX effect.
3.3. 5-HT3 receptor antagonist inhibited the DEX-induced glutamate release
of synaptosomes from the rat's prelimbic cortex
The effect of the 5-HT3 receptor antagonist MDL72222 (30 μM) was
observed on the DEX-induced glutamate release. The results showed
that in the presence of MDL72222 (30 μM), the DEX-induced glutamate
release of synaptosomes was completely inhibited (Fig. 3A, n=6). Theaverage concentration of glutamate after the application of DEX in the
presence ofMDL72222was 10.91±1.06 nmol/mg,whichwas statistical-
ly signiﬁcant from DEX alone (27.29±5.22 nmol/mg) (Fig. 3B, n=6,
pb0.05). These results suggested that 5-HT3 receptor might be involved
in the mechanism of DEX.
3.4. Ca2+ played an important role in the DEX-induced glutamate release
of synaptosomes from the rat's prelimbic cortex
It has been reported that the 5-HT3 receptor was the only ligand-
gated ion channel receptor for serotonin, and had high calcium perme-
ability on presynaptic nerve terminals [30]. The intrasynaptosomal
Ca2+ might have the downstream pathway of 5-HT3 receptor in the
mechanism of DEX. To test this hypothesis, the inﬂuence of the removal
of extracellular Ca2+ by the Ca2+-free medium containing EGTA [31]
was observed on the DEX-induced glutamate release of synaptosomes.
The results showed that the Ca2+-free medium containing EGTA
(1 mM) alone had no effects on the glutamate release of synaptosomes,
but it abolished DEX-induced glutamate release (Fig. 4A, n=4). The
average concentration of glutamate after the application of DEX in the
presence of EGTA was 6.71±1.30 nmol/mg, which was statistically
signiﬁcant from DEX alone (16.41±1.36 nmol/mg) (Fig. 4B, n=4,
pb0.05). These results conﬁrmed that Ca2+ was one of the important
factors in the mechanism of the effect of DEX.
Fig. 5. Inﬂuence of the β3 adrenergic receptor agonist on the DEX-induced glutamate release of synaptosomes from the rat's prelimbic cortex. A: the time course of the action of
amibegron (10 μM) on the DEX (3 μM)-induced glutamate release (n=6). B: the average results in a group of cells; amibegron inhibited the DEX-induced glutamate release sig-
niﬁcantly. The DEX alone group compared to amibegron+DEX group, n=6, #pb0.05. C: time course of the effect of amibegron (10 μM) on the intrasynaptosomal Ca2+ concen-
tration in the synaptosomes from the rat's prelimbic cortex and the inﬂuence of amibegron on the DEX-induced elevation of Ca2+ concentration (n=6). D: the average Ca2+
concentration of the effect of the DEX and amibegron+DEX; the DEX group compared to amibegron+DEX group, pb0.05; n=6.
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we furthermonitored the effect of DEXon intrasynaptosomal Ca2+ con-
centration. The results showed that DEX elevated the Ca2+ concentra-
tion (Fig. 4C red arrow). However, in the presence of 5-HT3 receptor
antagonist MDL72222 (30 μM), the DEX-induced Ca2+ elevation was
blocked (Fig. 4C, blue arrow). As shown in Fig. 4D, the average percentage
of the Ca2+ concentration after the application of DEX in the presence of
MDL72222 was 3.21±1.22%, which was statistically signiﬁcant as
compared to the DEX alone (34.28±3.76%) (n=6, pb0.05). These
results suggested that the inﬂux of extrasynaptosomal Ca2+ was medi-
ated by 5-HT3 receptors and 5-HT3 receptor-induced Ca2+ inﬂux was
the downstream pathway of the DEX-induced glutamate release of
synaptosomes from the rat's prelimbic cortex.
3.5. β3 adrenergic receptor agonist completely inhibited the DEX-induced
glutamate release of synaptosomes from the rat's prelimbic cortex
Previous studies have shown that β3 adrenergic receptors may be
involved in the depression [32]. In the present study, we observed the ef-
fect of amibegron (SR58611A), a selective β3 receptor agonist, on the
DEX-induced glutamate release. The results showed that amibegron
(10 μM) [33] alonehadnoeffect on the glutamate release, but it abolished
the DEX-induced glutamate release (Fig. 5A, n=6). The average concen-
tration of glutamate after the application of DEX in the presence of
amibegron was 11.75±0.94 nmol/mg, which was statistically signiﬁcant
from DEX alone (30.42±5.13 nmol/mg) (Fig. 5B, n=6, pb0.05). These
results suggested that β3 receptor may be involved in the regulative
mechanism of DEX.3.6. Gs protein inhibitor blocked the inhibitory effect of β3 adrenergic
receptor agonist on the DEX-induced glutamate release of synaptosomes
from the rat's prelimbic cortex
β3 adrenergic receptors are involved in the activation of adenylate
cyclase (AC) through the action of the G proteins of the type Gs [34].
To test whether the effect of DEX on the glutamate release was regulat-
ed by the downstream signal pathway of β3 receptors, we observed the
inﬂuence of NF449 (100 μM) [35] on the inhibitory effect of amibegron
(10 μM) on the DEX-induced glutamate release. NF449 (100 μM) alone
had no effects on the glutamate release (Fig. 6A; n=6). NF449 had no
effects on theDEX-induced glutamate release (Fig. 6A; n=6). However,
in the presence of NF449, the inhibitory effect of amibegron on the
DEX-induced glutamate releasewas eliminated (Fig. 6A; n=6). The av-
erage concentration of glutamate of NF449+amibegron+DEX group
was 31.01±0.91 nmol/mg, which was not statistically signiﬁcant
from DEX alone (27.63±3.16 nmol/mg) (Fig. 6B, n=6, p>0.05).
These results suggested that amibegron inhibited the DEX-induced glu-
tamate release via activation of Gs protein.
3.7. AC inhibitor blocked the inhibitory effect of β3 adrenergic receptor
agonist on the DEX-induced glutamate release of synaptosomes from
the rat's prelimbic cortex
We further observed the inﬂuence of AC inhibitor SQ22536
(100 μM) [36] on the inhibitory effect of amibegron on the DEX-
induced glutamate release. SQ22536 (100 μM) alone had no effects on
the glutamate release (Fig. 6C; n=6). SQ22536 had no effects on the
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ence of SQ22536, the inhibitory effect of amibegron on the
DEX-induced glutamate release was eliminated (Fig. 6C; n=6). The av-
erage concentration of glutamate of SQ22536+amibegron+DEX
group was 31.12±1.92 nmol/mg, which was not statistically signiﬁ-
cant from DEX alone (27.61±3.81 nmol/mg) (Fig. 6D, n=6, p>0.05).
These results suggested that ACwas the downstreampathway of the in-
hibitory effect of amibegron on the DEX-induced glutamate release.
3.8. PKA inhibitor blocked the inhibitory effect of β3 adrenergic receptor
agonist on the DEX-induced glutamate release of synaptosomes from the
rat's prelimbic cortex
To study the downstream events of the activation of AC after
amibegron, we observed the inﬂuence of the PKA inhibitor H89
(1 μM) [37] on the inhibitory effect of amibegron on the DEX-induced
glutamate release. H89 alone had no effects on the glutamate release
(Fig. 6E; n=4). H89 had no effects on the DEX-induced glutamate
release (Fig. 5E; n=4). However, in the presence of H89, the inhibitory
effect of amibegron on the DEX-induced glutamate release was elimi-
nated (Fig. 6E; n=4). The average concentration of glutamate of
H89+amibegron+DEX group was 22.59±2.97 nmol/mg, which was
not statistically signiﬁcant from DEX alone (24.60±2.37 nmol/mg)Fig. 6. Inﬂuence of the Gs protein inhibitor, the AC inhibitor, the PKA inhibitor and the PKA ago
tamate release of synaptosomes from the rat's prelimbic cortex. A: the time course of the acti
glutamate release (n=6). B: the average results in a group of cells, and the effect of the DEX on
effect of amibegron on the DEX-induced glutamate release signiﬁcantly. The DEX alone group c
tion of SQ22536 (100 μM)on the inhibitory effect of amibegron on theDEX (3 μM)-inducedglu
glutamate release in the presence of SQ22536+amibegron. SQ22536 blocked the inhibitory eff
compared to SQ22536+amibegron+DEX group, n=6, p>0.05. E: the time course of the actio
mate release (n=4). F: the average results in a group of cells and the effect of the DEX on the g
amibegron on the DEX-induced glutamate release signiﬁcantly. The DEX alone group compar
forskolin (20 μM) on the DEX (3 μM)-induced glutamate release (n=6). H: the average resul
The DEX alone group compared to forskolin+DEX group, n=6, #pb0.05.(Fig. 6F, n=4, p>0.05). These results suggested that PKA was the
downstream pathway of the inhibitory effect of amibegron on the
DEX-induced glutamate release.
3.9. PKA activator completely inhibited the DEX-induced glutamate release
of synaptosomes from the rat's prelimbic cortex
To determine the role of PKA, we further observed whether PKA
agonist forskolin (20 μM) [36] may simulate the inhibitory effect of
amibegron. The results showed that forskolin alone had no effect on
the glutamate release, but it abolished the DEX-induced glutamate
release (Fig. 6G, n=6). The average concentration of glutamate after
the application of DEX in the presence of forskolin was 9.15±
0.52 nmol/mg, which was statistically signiﬁcant from DEX alone
(23.93±4.74 nmol/mg) (Fig. 6H, n=6, pb0.05). These results con-
ﬁrmed that PKA may be involved in the regulative mechanism of DEX.
3.10. β3 adrenergic receptor agonist completely inhibited the DEX-induced
elevation of Ca2+ level of synaptosomes from the rat's prelimbic cortex
To study the possible relationship between β3 adrenergic receptor
pathway and 5-HT3 receptor pathway, we further observed the inﬂu-
ence of amibegron on the DEX-induced Ca2+ elevation. The resultsnist on the inhibitory effect of the β3 adrenergic receptor agonist on the DEX-induced glu-
on of NF449 (100 μM) on the inhibitory effect of amibegron on the DEX (3 μM)-induced
the glutamate release in the presence of NF449+amibegron. NF449 blocked the inhibitory
ompared to NF449+amibegron+DEX group, n=6, p>0.05. C: the time course of the ac-
tamate release (n=6). D: the average results in a groupof cells; the effect of the DEXon the
ect of amibegron on theDEX-induced glutamate release signiﬁcantly. The DEX alone group
n of H89 (1 μM) on the inhibitory effect of amibegron on the DEX (3 μM)-induced gluta-
lutamate release in the presence of H89+amibegron. H89 blocked the inhibitory effect of
ed to H89+amibegron+DEX group, n=4, p>0.05. G: the time course of the action of
ts in a group of cells; forskolin inhibited the DEX-induced glutamate release signiﬁcantly.
Fig. 6 (continued).
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However, in the presence of amibegron, the increased effect of DEX on
Ca2+ level was inhibited (Fig. 5C) which suggested that the agonist of
Gs receptor might inhibit the 5-HT3 receptor of synaptosomes. As
shown in Fig. 5D, the average percentage of the Ca2+ concentration
after the application of DEX in the presence of amibegron was 5.83±
0.93%, which was statistically signiﬁcant as compared to the DEX
alone (27.31±2.87%) (n=6, pb0.05).
3.11. DEX had no effect on the expression of GR, 5-HT3 receptor, and β3
adrenergic receptors of synaptosomes from the rat's prelimbic cortex
We also examined the expression of GR, 5-HT3 receptor, and β3
adrenergic receptors in synaptosomes from the rat's prelimbic cortex
in the control and DEX-treated synaptosomes using Western blotting.
The results showed that the amount of GR, 5-HT3 receptor, and β3
adrenergic receptor expression of DEX-treated synaptosomes was not
statistically signiﬁcant from the control. The percentage of the glucocor-
ticoid receptor/β-actin was 115.5±16.1% in DEX group, 5-HT3 recep-
tor/β-actin was 102.4±15.7% in DEX group, β3 receptor/β-actin was
108.1±12.1% inDEX group (n=5, p>0.05, comparedwith the control;
Fig. 7). These results suggested that DEXhad no effect on the expression
of GR, 5-HT3 receptor, and β3 adrenergic receptors in synaptosomes
during the duration of our experiment.
4. Discussion
In the present study, we have demonstrated that stress hormone
DEX increased the glutamate release of synaptosomes from the rat'sprelimbic cortex in a dose-dependent manner. The mechanisms that
shaped the presynaptic signals and glutamate release in response to
the DEXwere identiﬁed. We have also suggested a possible regulation
mechanism for DEX's action. To our knowledge, this is the ﬁrst report
to reveal these pathways (Fig. 8).
The prelimbic regions of the cerebral cortex were expected to be
particularly associated with cognitive abnormalities that were seen in
many patients with depression, in the present experiment, the effect
of DEX was observed on the presynaptic glutamate release of the
prelimbic cortex. The results showed that DEX increased the glutamate
release of synaptosomes signiﬁcantly. The increased effect of DEX on
the glutamate release of synaptosomes from the rat's prelimbic cortex
was dose dependent, with a threshold concentration between 0.1 μm
and 10 μm and a peak glutamate concentration of 3 μm. These results
are consistent with those reported for acute stress-induced increase of
the glutamate release [38].
Musazzi et al. also reported that acute footshock stress up-
regulated depolarization-evoked release of glutamate from synapto-
somes of the prefrontal/frontal cortex. Stress-induced increase of
the glutamate release was dependent on stimulation of glucocorticoid
receptor by corticosterone [38]. Thus it is possible that DEX produced
its effect by the activation of GR. To explore the possible sites of the
action of DEX, we ﬁrst observed the inﬂuence of the antagonist of
GR on the DEX-induced glutamate release. The results showed that
both the GR antagonist RU486 and GR siRNA had no effect on the
DEX-induced glutamate release, which excluded the possibility of
GR. The ﬁnding that DEX increased the glutamate release of synapto-
somes from the prelimbic cortex not by GR was unexpected because
GR was the most important regulator of the HPA axis negative
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depression in both in vitro and in vivo studies [39]. However, two
mechanisms have been proposed to characterize the actions of DEX
[40]. The ﬁrst is the genomic mechanism of actions that involve the
diffusion or transport of DEX across the membrane into the neuron
and activation of GR. The second is the nongenomic mechanism of ac-
tion that involves the direct actions of DEX on membrane protein toalter the release of neurotransmitters. A customary rule to distinguish
the two mechanisms is that the genomic effects are delayed in onset
and the nongenomic effects are rapid in onset. Therefore, based on
the present result that the effect of DEX on the glutamate release is
rapid, it is more likely that this effect of DEX may involve nongenomic
mechanisms.
The possible nongenomic mechanism was that DEX produced its
increased effect by the activation of 5-HT3 receptors because a previ-
ous study reported that presynaptic 5-HT3 receptors controlled neu-
rotransmitter release [41] and 5-HT3 receptors were involved in the
effect of antidepressants [42,43]. The present results that 5-HT3
receptor antagonist MDL72222 blocked the DEX-induced glutamate
release veriﬁed the hypothesis.
The 5-HT3 receptor is the only ligand-gated ion channel receptor
for serotonin and it has high calcium permeability on presynaptic
nerve terminals [30]. The downstream signal transduction pathway
of the activation of 5-HT3 receptors by DEX might be mediated by
extrasynaptosomal Ca2+ inﬂux through 5-HT3 receptors. In the
experiment, the extracellular Ca2+ was removed from the Ca2+-free
medium containing EGTA and the Ca2+ concentration was also
monitored. The results showed that EGTA blocked the DEX-induced
glutamate release which suggested that the effect of DEX was
Ca2+-dependent. The result that MDL72222 completely blocked the
DEX-induced Ca2+ elevation added to the ﬁndings that the DEX-
induced Ca2+ elevationwasmediated by 5-HT3 receptors. These results
conﬁrmed the hypothesis and suggested that the DEX-induced gluta-
mate release was dependent on the inﬂux of extrasynaptosomal Ca2+
mediated by 5-HT3 receptors and 5-HT3 receptor-induced Ca2+ inﬂux
was the downstream pathway of the DEX-induced glutamate release
of synaptosomes from the rat's prelimbic cortex.
Further studies investigated the possible regulation of the DEX-
induced glutamate release. The involvement of the noradrenergic sys-
tem in depressive disorders has been frequently shown [44,45].
Recently, it has been shown that the β3 receptor may also contribute
since amibegron (SR58611A), a selective β3 receptor agonist, has
antidepressant-like effects. Two separate studies have reported that
amibegron has antidepressant like effects in the forced swim test,
using a modiﬁcation of the Porsolt [32,46]. Therefore, it is most likely
that β3 adrenergic receptors may regulate the DEX-induced gluta-
mate release. The hypothesis was tested by observing the inﬂuence
of β3 adrenergic receptor agonist amibegron on the DEX-induced
glutamate release, which showed that amibegron blocked the effect
of DEX on the glutamate release completely. The fact that β3 receptor
agonist blocked the effect of DEX on the glutamate release indicated
that β3 receptor was not involved in the downstream pathway of the
effect of DEX, but only regulated the DEX-induced glutamate release.
Otherwise, β3 receptor agonist should mimic the effect of DEX on the
glutamate release of synaptosomes from the prelimbic cortex.
Activation of the β3 adrenergic receptor by epinephrine, norepineph-
rine, or speciﬁc agonists typically results in the Gs-dependent activation
of adenylate cyclase, increases in intracellular cAMP, and stimulation of
protein kinase A (PKA) [34,47]. PKA, in turn, regulates various proteins.
To investigate the underlying mechanism of the regulation of β3 adren-
ergic receptor on the DEX-induced glutamate release, we observed theFig. 7. Expression of glucocorticoid receptor (GR), 5-HT3 receptor, and β3 adrenergic
receptors in synaptosomes from the rat's prelimbic cortex in the control and
DEX-treated synaptosomes using Western blotting. A–C, top, average density of the
corresponding protein bands after normalization by β-actin protein in the control
and DEX-treated synaptosomes. Bottom, immunoblots of the GR protein levels in the
prelimbic cortex after labeling with the antibody in the control and DEX-treated synap-
tosomes. A, expression of GR in synaptosomes (n=5) from the prelimbic cortex in the
control and DEX-treated groups using Western blotting (p>0.05, compared with the
control). B, expression of 5-HT3 receptors in synaptosomes (n=5) from the prelimbic
cortex in the control and DEX-treated groups using Western blotting (p>0.05, com-
pared with the control). C, expression of β3 adrenergic receptors in synaptosomes
(n=5) from the prelimbic cortex in the control and DEX-treated groups using Western
blotting (p>0.05, compared with the control).
Fig. 8. Schematic representation of the possible mechanism and regulation of the DEX-induced glutamate release of synaptosomes from the rat's prelimbic cortex. DEX could increase
presynaptic glutamate release by activating presynaptic 5-HT3 receptors and it could lead to the elevation of theCa2+ concentration (blue arrow). The activation ofβ3 adrenergic receptors
inhibited the DEX-induced glutamate release completely via the Gs–AC–PKA signal transduction pathway (red arrow).
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nist on the DEX-induced glutamate release respectively. The results
showed that Gs protein inhibitor NF449, AC inhibitor SQ22536 and
PKA inhibitor H89 blocked the inhibitory effect of β3 adrenergic recep-
tor agonist amibegron on the DEX-induced glutamate release, while
PKA agonist forskolin couldmimic the effect of DEX to increase the glu-
tamate release of synaptosomes from the prelimbic cortex. These re-
sults demonstrated that the β3 receptor produced its inhibitory effect
on the DEX-induced glutamate release by Gs–AC–PKA signal transduc-
tion pathway. To further study the possible crosstalk between these
two pathways, we observed the effect of amibegron on the
DEX-induced Ca2+ elevation. The results showed that the increased ef-
fect of DEX on Ca2+ level was inhibited by amibegron. These results
suggested that Gs–AC–PKA pathway might affect the 5-HT3 receptor
mediated Ca2+ inﬂux which needs further study.
In summary, the present data suggested that the acute application
of DEX increased the glutamate release of synaptosomes from
the rat's prelimbic cortex in a dose-dependent manner. DEX produced
the increased effect on the glutamate release not by GR, but through the
activation of the 5-HT3 receptors which led to the inﬂux of
extrasynaptosomal Ca2+. However, the effect of DEX on the glutamate
release could be regulated by noradrenergic system. The activation of
β3 adrenergic receptors inhibited the DEX-induced glutamate release
completely via Gs–AC–PKA signal transduction pathway (Fig. 7).4.1. Signiﬁcance
It has been known that stress hormone, glutamatergic system, seroto-
nergic system and the noradrenergic system are involved in depressive
disorders. However, the relationship among these is still unclear. The
present ﬁnding that DEX increases the presynaptic glutamate release by
5-HT3 receptors which can be regulated by β3 adrenergic receptors is of
signiﬁcance for understanding the crosstalk among these systems. Inaddition, the present ﬁnding provides new clues for the treatment of
stress-related depression.
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